Ingredients

Suppliers of reagents and buffers need to adhere to quality systems.

Biocatalysis is an increasingly attractive option in pharmaceutical synthesis.

Platinum group (and other precious) metal catalysts are inherently expensive, so why not recover and recycle?

How can companies avoid the risks of HPAPI containment and handling?

How is the Indian pharmaceutical industry adapting to meet new demands?

Newly published research suggests that some excipients may be more "active" than previously thought.

Can a medieval medicament find use as a modern antibacterial?

How can manufacturers avoid frustrating and inadvertent changes to the solid forms of APIs?

It is essential that drug development incorporates the patient view.

We need to optimize and then accelerate HPAPI drug product development. Alyn McNaughton from Lonza tells us more.